Liquid Biopsy Utility for the Surveillance of Cutaneous Malignant Melanoma Patients

Cutaneous melanoma is one of the highest incident-rate cancers with increasing prevalence in Western societies. Despite the advent of new approved therapeutics, the 5-year overall survival rate of stage IV melanoma patients remains below 15%. Current treatments for late-stage disease have shown higher efficacy when treated at a lower disease burden. Thus, blood-based biomarkers capable of detecting melanoma prior to clinically evident distant metastasis, will improve the treatment and outcomes for melanoma patients.
Source: Molecular Oncology - Category: Cancer & Oncology Authors: Tags: Review Source Type: research